Bone metabolism

Product name

Helical Peptide (Quidel®)

Helical Peptide 620-633 from the alpha 1 chain of Collagen Type-I

Range20 - 2500 µg/l
Sensitivity8 µg/l
Incubation time19-25 hours
Sample volume20 µl
Sample type

Urine, cell culture

Sample preparation

Collect preservative-free urine before 10 a.m. Keep specimen refrigerated at 2-8°C for storage up to 7 days. For long-term storage freeze sample at -20°C or below.

Reference values

Adults (25 - 34 years), average 50.7µg/mmol Cr 
                                     (S.D. = 23.8 µg/mmol Cr).

Reference values from children are available.


Human, rat, rabbit, guinea pig, cat, dog, porcine, goat, sheep, bovine, horse, monkey, baboon, mouse, cynomolgus macaque

Cross reaction

90% cross-reactivity with alpha1-(III) homologous peptides, no cross-reaction with alpha1-(II)- or alpha2-(I)homologous peptides.

Tests96 Tests
Intended use

The organic matrix of bone contains approximately 90% of type-I collagen, a helical, hetero-trimeric molecule comprising two α1 chains and one α2 chain. During bone resorption the collagen molecule is degraded and peptides of various molecular weights are released into the circulation, that are further degraded and/or released into the urine. A peptide consisting residues 620-633 derived from the helical region of the α1 chain was isolated from the urine of a patient with Paget’s disease. Thereafter, a synthetic peptide α1(I) 620-633 has been used as immunogen for monoclonal antibody production. These antibodies were used to develope a competitive immunoassay for the measurement of the Helical Peptide in human urine for bone metabolism studies. Increased levels of Helical Peptide have been found in urine of postmenopausal women with osteoporosis and urine of patients with Paget's disease. Both diseases are characterized by an enhanced degradation of bone collagen. Helical Peptide concentration decreased during estrogen or bisphosphonate therapies, indicating the anti-resorptive effect of these therapies.

Product informations

Back to overview